Abstract
Objective We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (± 19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T. rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion Although the small number of subjects is an important limitation in our study. DTNBP1 does not seem to be involved in acute antimanic efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 102-105 |
| Number of pages | 4 |
| Journal | Psychiatry Investigation |
| Volume | 5 |
| Issue number | 2 |
| Publication status | Published - Jun 2008 |
Fingerprint
Keywords
- Antimanic agents
- Bipolar disorder
- Dysbindin
- Pharmacogenetics
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry
Cite this
Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. / Yun, Dong Hwan; Pae, Chi Un; Drago, Antonio; Mandelli, Laura; De Ronchi, Diana; Patkar, Ashwin A.; Paik, In Ho; Serretti, Alessandro; Kim, Jung Jin.
In: Psychiatry Investigation, Vol. 5, No. 2, 06.2008, p. 102-105.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder
AU - Yun, Dong Hwan
AU - Pae, Chi Un
AU - Drago, Antonio
AU - Mandelli, Laura
AU - De Ronchi, Diana
AU - Patkar, Ashwin A.
AU - Paik, In Ho
AU - Serretti, Alessandro
AU - Kim, Jung Jin
PY - 2008/6
Y1 - 2008/6
N2 - Objective We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (± 19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T. rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion Although the small number of subjects is an important limitation in our study. DTNBP1 does not seem to be involved in acute antimanic efficacy.
AB - Objective We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (± 19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T. rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion Although the small number of subjects is an important limitation in our study. DTNBP1 does not seem to be involved in acute antimanic efficacy.
KW - Antimanic agents
KW - Bipolar disorder
KW - Dysbindin
KW - Pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=46949101020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46949101020&partnerID=8YFLogxK
M3 - Article
C2 - 20046352
AN - SCOPUS:46949101020
VL - 5
SP - 102
EP - 105
JO - Psychiatry Investigation
JF - Psychiatry Investigation
SN - 1738-3684
IS - 2
ER -